Zydus Lifesciences has secured a non-exclusive patent license from Takeda Pharmaceutical to market Vonoprazan, a novel Potassium Competitive Acid Blocker (P-CAB), in India for the treatment of gastroesophageal reflux disease (GERD). This move expands Zydus’s portfolio of gastrointestinal therapies and offers a new treatment option for patients in India, where GERD is prevalent.
The Indian pharmaceutical market experienced robust growth in 2024, with demand for anti-infective, gastrointestinal, and respiratory drugs surging by double digits. The overall industry saw an 8.8% increase, driven by positive growth across various therapeutic categories. While cardiac drug sales remained stable, painkillers witnessed a seasonal spike during the monsoon months. The report highlights Augmentin as the top-selling drug and points to a strong performance by leading players in June 2024.
A man facing DUI charges has been acquitted after he was diagnosed with auto-brewery syndrome, a rare condition that causes carbohydrates to ferment in the gastrointestinal tract, creating alcohol. Despite having high levels of alcohol in his system, the defendant showed no signs of intoxication. Three doctors confirmed the diagnosis, and the judge ruled in his favor.
